(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. - Wikidata - awgldk - TriplyDB

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

http://www.wikidata.org/entity/Q35452165

about

(123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases Vesicular integrity in Parkinson's disease Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys Imaging improves diagnosis of dementia with lewy bodies Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.Imaging Parkinson's disease below the neck.REM sleep behavior disorder in Japanese patients with Parkinson's disease: a multicenter study using the REM sleep behavior disorder screening questionnaire.Dysautonomia in Parkinson disease Nonmotor Symptoms in Patients with PARK2 Mutations.Diagnostic accuracy of apparent diffusion coefficient and 123I-metaiodobenzylguanidine for differentiation of multiple system atrophy and Parkinson's disease.123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations Ambulatory ECG and analysis of heart rate variability in Parkinson's disease.Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease.Abnormal baroreceptor-mediated vasopressin release as possible marker in early diagnosis of multiple system atrophy.Recent progress of imaging agents for Parkinson's disease.Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy.On the Utility of MIBG SPECT/CT in Evaluating Cardiac Sympathetic Dysfunction in Lewy Body Diseases.Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity?123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder Prevalence and clinical implication of microbleeds in dementia with lewy bodies in comparison with microbleeds in Alzheimer's disease.Systemic postganglionic adrenergic studies do not distinguish Parkinson's disease from multiple system atrophy Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.Single photon-emission computed tomography imaging in early Parkinson's disease.Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade.Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.Multi-organ autonomic dysfunction in Parkinson disease.α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.Expanding morphological dimensions in neuropathology, from sequence biology to pathological sequences and clinical consequences.MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.Biomarkers for the diagnosis and management of Parkinson's disease.Oxidized DJ-1 as a possible biomarker of Parkinson's disease (123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review.Imaging Systemic Dysfunction in Parkinson's Disease.Iodine-123 metaiodobenzylguanidine imaging can predict future cardiac events in Japanese patients with Parkinson's disease.Diagnostic and Pathophysiological Impact of Myocardial MIBG Scintigraphy in Parkinson's Disease.Lowered cardiac sympathetic nerve performance in response to exercise in Parkinson's disease.

P2860

Q28067098-93CFBC34-F130-45B4-B814-3AE24FAD5326 Q28385737-B9696851-C437-46D2-87DF-C6DD066648AC Q31059759-C6D9EF84-E740-4F81-96D4-B8D505D13378 Q33530076-72ED8DA3-F2CE-439A-BA59-369F4E2C5F91 Q33583061-A9A6623D-87B0-47CA-821C-FF41942407B9 Q33693399-59A45129-493A-4F53-93AC-77D87BA3BEBE Q33767061-BBAE2A9B-2044-4667-801F-16D9A730569D Q34246009-BB236BC7-0F9F-42E6-905B-620B668BDAA3 Q34463831-C3E855FB-BEC9-4E41-8F72-68DD3F9F1CFB Q34521178-998D0906-3E95-4BDB-8E39-D55818499CA1 Q34683979-C94C427F-74D9-49CC-B9B4-4EBF5F83AE4C Q35004642-3BB8CE6E-3571-485A-82CE-4E978CA07088 Q35461193-C9136D57-27C5-43B3-82BB-51FEA98C15B3 Q35472413-2C93ACBD-DA9C-47C3-B0C5-5743CF17C4C5 Q35560351-CFF268B5-C2DB-45F4-B6A8-7D4F20DED384 Q35595426-0675EF0B-0F39-445C-9A9D-8D20E41444DD Q35630950-CA89EB44-CE2A-4706-B801-B2096BA7AA75 Q35649302-42D5BC15-1C8B-460C-B260-F0B7187DB6CB Q35923029-F6FE8B01-1E02-4886-9420-17147A46D11B Q35982744-805CA517-9B18-42A9-B44C-3CC3420168E0 Q36011221-93F222B7-EA35-459C-9A73-27501FCA9C2B Q36117002-303E6CBE-A5F1-4FCD-AF3A-895719906D9E Q36681412-EB1FAECC-9728-4173-BB59-E415F0E669F3 Q36896644-3A85CBE3-FA79-4E2F-98E4-6F89230F36ED Q37186158-B92BD56F-4F6E-40E4-918C-6D0D9BDE9890 Q37243261-1BABDC70-AEB3-4DA4-AD38-CAEACEA23209 Q37352055-E16037BD-4EF8-46AA-93B8-6F1C96E4A1B4 Q37514436-6936DF1F-9437-44C3-9DB3-EC990D87CE6C Q37711062-7D89AC3F-099E-4073-B1BD-6CE446396A68 Q37790044-52BC8042-CA41-4E4A-85DD-CFC09F16AE06 Q37820120-DFCA66EB-CE79-4619-A305-0D581CA6CA52 Q37880198-88E42DAB-1886-4139-8659-84744BF5A7EB Q37906394-20DCA0B4-1C16-4201-9F90-B040DD2FA22A Q38093247-2096CD55-2197-459D-8C1D-675F180B592E Q38217361-7215DF60-5516-4395-ABC4-74A29C53CEEE Q38531996-3E16558A-87B4-4BF9-853F-424454026D4F Q38807024-A8EFFB09-E7FF-46DC-9B07-25E93ECC88A5 Q39533182-95B2A396-4141-482C-8E33-BE12B7B63B87 Q42408447-09C8AD76-97B5-40E5-8726-2241B4390C89 Q42970937-07FE344F-9C77-4440-8785-46B0B05B4874

P2860

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

http://www.wikidata.org/entity/Q35452165

description

1999 nî lūn-bûn

@nan

1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

@ast

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

@en

type

label

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

@ast

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

@en

altLabel

123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease

@en

prefLabel

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

@ast

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

@en

P1433

Q35452165-2C28A452-1329-4E29-A47E-5CD873A70D6A

P1476

Q35452165-152C7A22-40E8-470E-9EA4-16271EF19E45

P2093

Q35452165-14877065-685D-4D08-B3A0-96B250DC1D40

Q35452165-209AA0FE-1B4B-4339-BEDB-499F46F9B670

Q35452165-8222F13D-98C6-4B08-985F-3AC29E221455

Q35452165-9108B8DD-4815-43BC-BEC6-A3F1C55952E6

Q35452165-E776468C-99A1-4036-98BE-7832F4E93B8B

P2860

Q35452165-1DFF489A-AE7D-41A2-9B48-4414FA56F6CF

Q35452165-1E008D41-74A1-478C-A74F-8F5D8580E648

Q35452165-28B351BB-6C75-4707-8D94-557DCA4DA4B7

Q35452165-363EF6AD-E0E5-4C24-A121-6936216D5B6A

Q35452165-59B6782D-F7BA-451A-8077-11DE26EFD898

Q35452165-5BC1EA67-E3C6-44D8-AAEF-329EEB4E356D

Q35452165-88821CA2-9713-469F-9F70-A133DA8D7B37

Q35452165-96A5E845-9885-4055-8649-67893FC97D1D

Q35452165-B2331B78-0CC6-4095-9FE6-5D391114591C

Q35452165-B5945E4F-1072-47E7-BF80-738E9788D66E

P304

Q35452165-690D58E3-C426-44F1-AE8D-9B052ABBF671

P31

Q35452165-478BFA5C-DF1F-4BD3-B35B-749657433885

P356

Q35452165-AEB43EA4-9185-4AFA-8EAC-F75146B760DA

P407

Q35452165-D4093F99-61BC-4CCD-902C-4E18611ECF19

P433

Q35452165-1C2D6F79-F261-4DEF-8B16-B36964B0918F

P478

Q35452165-14B0F84E-7B33-41C8-B98C-92ED8F5CB62F

P577

Q35452165-2119E62A-BE19-4601-B371-2D2E9C206387

P5875

Q35452165-026AF343-D697-4323-B1C9-7C79F9608C5C

P698

Q35452165-B2F6719F-DFA2-435A-B946-9E1B85A0CB65

P921

Q35452165-61AA8A03-1369-44F2-BD90-D04710DCDFE0

P932

Q35452165-89C41F9D-E6E4-4DFA-9262-B765D6B9BEAA

P356

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

@en

P2093

Mizusawa H

http://www.w3.org/2001/XMLSchema#string

Nakade S

http://www.w3.org/2001/XMLSchema#string

Orimo S

http://www.w3.org/2001/XMLSchema#string

Ozawa E

http://www.w3.org/2001/XMLSchema#string

Sugimoto T

http://www.w3.org/2001/XMLSchema#string

P2860

Lateral horn cells in progressive autonomic failure

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity.

Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease--a retrospective comparison.

Ultrastructure of Lewy bodies in the stellate ganglion.

Parkinson's disease: distribution of Lewy bodies and monoamine neuron system.

The hypothalamus in Parkinson disease.

Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine.

The rostral mesencephalon in Parkinson's disease and Alzheimer's disease.

P304

189-194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.67.2.189

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247695346

http://www.w3.org/2001/XMLSchema#string

P698

10406987

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

1736461

http://www.w3.org/2001/XMLSchema#string